You are here

Article Text

Article menu

Download PDFPDF

Correspondence response
Response to: “How to communicate in science” by Klareskog et al
Free
  1. René Toes1,
  2. David S Pisetsky2
  1. 1 Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  2. 2 Medicine, Medical Research Service, Durham, North Carolina, USA
  1. Correspondence to Dr René Toes, Rheumatology, Leiden University Medical Center, Leiden 2333 ZA, The Netherlands; r.e.m.toes{at}lumc.nl

https://doi.org/10.1136/annrheumdis-2019-216045

Statistics from Altmetric.com

    We have read with interest the reply by Klareskog et al, ‘How to communicate in science’,1 to our editorial, ‘Pathogenic effector function of ACPA: where do we stand?’.2 We agree with the authors that further studies are needed to elucidate the potential contributions of anticitrullinated protein antibodies (ACPAs) to the signs and symptoms of rheumatoid arthritis. We think that the effector functions of ACPAs is an exciting area of investigation and that these studies will provide important insights into disease pathogenesis and lead to new biomarkers to subtype patients, assess disease activity and monitor therapy.

    References

    1. ↵
      2. Klareskog L ,
      3. Catrina AI ,
      4. Svensson C , et al
      . How to communicate in science. Ann Rheum Dis 2020;79:e164.
    2. ↵
      2. Toes R ,
      3. Pisetsky DS
      . Pathogenic effector functions of AcpA: where do we stand? Ann Rheum Dis 2019;78:716–21.doi:10.1136/annrheumdis-2019-215337
      OpenUrlFREE Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • Correspondence
      How to communicate in science
      Lars Klareskog Anca Irinel Catrina Camilla Svensson Vivianne Malmstrom
      Annals of the Rheumatic Diseases 2019; 79 e164-e164 Published Online First: 13 Aug 2019. doi: 10.1136/annrheumdis-2019-216016